Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  66 results for ""Neuen BL""

Your Filters

Subject : biomarkers Subject : diabetes mellitus, type 2 Subject : glucose intolerance Subject : renal insufficiency, chronic Filter by : Author
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease.

  • Authors : Neuen BL; The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N.).; Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N.).

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/epidemiology

  • Source: Circulation [Circulation] 2024 Apr 16; Vol. 149 (16), pp. 1238-1240. Date of Electronic Publication: 2024 Apr 15.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0147763 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.

  • Authors : Sharma A; Centre for Outcomes Research and Evaluation Research Institute of the McGill University Health Centre Montreal QC Canada.; Division of Cardiology McGill University Health Centre, McGill University Montreal QC Canada.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

  • Source: Journal of the American Heart Association [J Am Heart Assoc] 2024 Feb 06; Vol. 13 (3), pp. e031586. Date of Electronic Publication: 2024 Jan 19.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.

  • Authors : Neuen BL; The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., H.J.L.H., R.A.F., C.A., B.N., V.P.).; Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N.).

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/adverse effects

  • Source: Circulation [Circulation] 2024 Feb 06; Vol. 149 (6), pp. 450-462. Date of Electronic Publication: 2023 Nov 12.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0147763 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations.

  • Authors : Beal B; Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.; Schutte AE

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/pharmacology ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications

  • Source: Current hypertension reports [Curr Hypertens Rep] 2023 Dec; Vol. 25 (12), pp. 429-435. Date of Electronic Publication: 2023 Nov 10.Publisher: Current Science, Inc Country of Publication: United States NLM ID: 100888982 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.

  • Authors : Fletcher RA; The George Institute for Global Health, UNSW, Sydney, New South Wales, Australia.; Jongs N

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/pharmacology ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/complications

  • Source: Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2023 Dec 01; Vol. 34 (12), pp. 1965-1975. Date of Electronic Publication: 2023 Oct 25.Publisher: Wolters Kluwer Health, on behalf of the American Society of Nephrology Country of Publication: United States NLM ID: 9013836 Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.

  • Authors : Koshino A; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands.; Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/diagnosis

  • Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2023 Nov 28; Vol. 22 (1), pp. 330. Date of Electronic Publication: 2023 Nov 28.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.

  • Authors : Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.; The George Institute for Global Health, Sydney, Australia.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/chemically induced

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Nov; Vol. 25 (11), pp. 3327-3336. Date of Electronic Publication: 2023 Aug 14.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.

  • Authors : Fletcher RA; The George Institute for Global Health, UNSW New South Wales Sydney Australia.; Arnott C

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/adverse effects

  • Source: Journal of the American Heart Association [J Am Heart Assoc] 2023 Jul 04; Vol. 12 (13), pp. e028516. Date of Electronic Publication: 2023 Jun 22.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Report

Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.

  • Authors : Yi TW; The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.; Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Subjects: Cardiovascular System* ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/complications ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/drug therapy

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Jul; Vol. 25 (7), pp. 2043-2047. Date of Electronic Publication: 2023 Apr 24.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.

  • Authors : Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; The George Institute for Global Health, Sydney, Australia. Electronic address: .

Subjects: Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy; Humans

  • Source: Kidney international [Kidney Int] 2023 Jul; Vol. 104 (1), pp. 181-188. Date of Electronic Publication: 2023 Apr 28.Publisher: Elsevier Country of Publication: United States NLM ID: 0323470 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  66 results for ""Neuen BL""